3 Best Performing ASX shares in week 7, 14 February 2022
Marc Kennis, February 21, 2022
Best performing ASX shares
This week’s best performing ASX shares are Netlinkz (ASX:NET), up 26.3%, Big River Gold (ASX:BRV), up 25%, and NRW Holdings (ASX:NWH), up 21.5%.
1. Netlinkz (ASX:NET)
Industry: Software & IT Services
Netlinkz (ASX:NET) is a networking vendor that provides secure and efficient cloud network solutions. The Netlinkz VSN solution is a NaaS (Network-as-a-Service) proposition that is user-centric, creating a per-user private network that is available, secure and performance optimised, for authorised users regardless of their location.
Market Cap: $70M
12 month high / low: $0.014 – $0.0477
2. Big River Gold (ASX:BRV)
Industry: Mineral Resources
Big River Gold Limited (BRV, formerly Crusader Resources Limited) is a minerals exploration and development company focused on advancing its wholly-owned Borborema Gold Project in Brazil.
Market Cap: $66M
12 month high / low: $0.20 – $0.46
3. NRW Holdings (ASX:NWH)
Industry: Industrial & Commercial Services
NRW Holdings Limited (NWH) is an Australian owned Group of companies providing diversified contract services to the resources and infrastructure sectors. Companies within the Group include NRW Civil & Mining, Golding, Action Drill & Blast, RCR Mining Technologies, DIAB Engineering and AES Equipment Solutions.
Market Cap: $952m
12 month high / low: $1.36 – $2.37
Learn more about ASX-listed stocks with
Stocks Down Under!
Subscribe to Stocks Down Under today!
No credit card needed and the trial expires automatically.
Blog Categories
Get the Latest Insider Trades on ASX!
Recent Posts
Nvidia Says US$1T by 2027, Here’s the Hardware Shift It’s Banking On
Nvidia’s US$1T Goal Just Raised the Stakes for Inference Nvidia CEO Jensen Huang has just held the company’s biggest annual…
AML3D (ASX:AL3) Record A$9.9m US Navy Shipbuilder Order Sparks a Rerate
Newport News Doubles Down, Four Arcemy X Systems Ordered AML3D surged today after announcing a A$9.9M contract with the US’s…
T-Cell Lymphoma is a very deadly cancer, but this ASX stock has a treatment in a Phase 2 trial!
Prescient Therapeutics‘ (ASX:PTX) trial of PTX-100 against T-Cell Lymphoma is well and truly underway now with 8 out of…